Dr. Silvia Pozzi on the State of Antibody Therapies for ALS

Antibodies are an essential part of our bodies’ defenses against diseases. They are specialized proteins that attack and kill foreign invaders like infectious bacteria and viruses.

Antibodies are normally naturally produced by our immune system in response to an infection. However, in recent years, scientists have learned to produce antibodies in a lab to treat a variety of diseases.  Several Antibody treatments have been investigated in ALS, including tegoprubart, which was invented by ALS TDI and recently successfully completed a phase 2a clinical trial.

Dr. Silvia Pozzi is Assistant Professor at the Université Laval’s Brain Research Center in Quebec City specializing in ALS Research. She recently was an author on a paper reviewing the current state of antibody therapies for ALS.  She joined us on Endpoints to discuss the current outlook for these therapies in the ALS space – as well as what the future might hold for these treatments.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.